Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Senescence-Associated Secretory Phenotype-mediated Oncogene-Induced Senescence, a Potential Barrier to Malignancy
FY 2022-23
Summary
Lung cancer is the most lethal cancer globally and in North America, causing more than 25% of cancer-related deaths. Considering most cases are diagnosed once malignancy has already occurred, viable treatment options for patients in stage 3 and above are severely needed. Lung cancer is often caused by mutations in the mitogen-activated protein kinase pathway. One such mutation arises in the BRAF gene, which is responsible for inappropriate cellular proliferation. BRAF mutations are known to induce an irreversible proliferative barrier that functions to control and reduce tumor progression. This blockade is referred to as oncogene-induced senescence (OIS). However, early mutations in the important tumor suppressor gene P53 often breach OIS. Recent data from genetically modified mouse models suggest that late-stage high-density tumors proliferate at a lower rate than early-staged tumors. These lower proliferative tumors showed similarities to non-proliferative senescent cells. We hypothesize that this could be due to the secretion of senescence-associated secretory phenotype molecules, or SASPs, able to dictate the behavior of neighboring cells. Thus, detailing the SASP gene repertoire and gaining further insight into their mechanism of action could provide crucial information to inhibit tumor malignancy and propagation. This project will come to life through the study of in vivo mouse models, cell culture, and more. The SASP pathway must imperatively be investigated, as it offers promising results that could impact late-stage patient outcomes in a variety of solid tumor cancer types.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
485917
Name
Manea Maria M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Senescence-Associated Secretory Phenotype-mediated Oncogene-Induced Senescence, a Potential Barrier to Malignancy
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brafv600e; Cancer; Lung Adenocarcinoma; Mitogen-Activated Protein Kinase Pathway; Oncogene-Induced Senescence; P53; Senescence; Senescence-Associated Secretory Phenotype; Tumor Density
Abstract
Lung cancer is the most lethal cancer globally and in North America, causing more than 25% of cancer-related deaths. Considering most cases are diagnosed once malignancy has already occurred, viable treatment options for patients in stage 3 and above are severely needed. Lung cancer is often caused by mutations in the mitogen-activated protein kinase pathway. One such mutation arises in the BRAF gene, which is responsible for inappropriate cellular proliferation. BRAF mutations are known to induce an irreversible proliferative barrier that functions to control and reduce tumor progression. This blockade is referred to as oncogene-induced senescence (OIS). However, early mutations in the important tumor suppressor gene P53 often breach OIS. Recent data from genetically modified mouse models suggest that late-stage high-density tumors proliferate at a lower rate than early-staged tumors. These lower proliferative tumors showed similarities to non-proliferative senescent cells. We hypothesize that this could be due to the secretion of senescence-associated secretory phenotype molecules, or SASPs, able to dictate the behavior of neighboring cells. Thus, detailing the SASP gene repertoire and gaining further insight into their mechanism of action could provide crucial information to inhibit tumor malignancy and propagation. This project will come to life through the study of in vivo mouse models, cell culture, and more. The SASP pathway must imperatively be investigated, as it offers promising results that could impact late-stage patient outcomes in a variety of solid tumor cancer types.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Manea, Maria M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~